Put companies on watchlist
Gerresheimer AG
ISIN: DE000A0LD6E6
WKN: A0LD6E
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Gerresheimer AG · ISIN: DE000A0LD6E6 · EQS - Company News (69 News)
Country: Germany · Primary market: Germany · EQS NID: 1258818
16 December 2021 10:01AM

Gerresheimer enters into agreement with major American biotech to develop an innovative pump for rare diseases



DGAP-Media / 16.12.2021 / 10:01


Gerresheimer enters into agreement with major American biotech to develop an innovative pump for rare diseases

  • Important agreement with significant sales and revenue potential
  • Development of a new pump to deliver a leading rare disease drug, using proven pump technology from Gerresheimer
  • Sensile pump by Gerresheimer designed to improve quality of life with ease of use
  • High existing patient demand for pump systems to deliver the productexpected to lead to prompt realization and implementation on the market
  • Long-term collaboration envisaged: a major American biotech relies on integral solution and innovation strength of Gerresheimer

Düsseldorf, December 16, 2021 - Gerresheimer has entered into an important agreement involving its Advanced Technologies division. An established US biotech company will rely on Gerresheimer's innovative strength and engineering expertise for the development of a new pump to deliver a leading drug for the treatment of rare diseases via continuous parenteral administration.

"This agreement is another important milestone on our way to becoming a solution provider for leading and innovative medical devices." said Dietmar Siemssen, CEO of Gerresheimer AG. "Our patented pump technology has already proven itself in use for Parkinson's therapy and in future we expect it will also help to improve the quality of life of people with rare diseases. Our broad portfolio for the pharma and biotech industry makes it possible to develop the best solution together with our customers and implement it with a perfect fit."

The pump for the continuous parenteral administration of the liquid drug will be specially adapted by Gerresheimer to the needs of patients with this rare disease. The sales and revenue model is divided into two phases. First, the American biotech will fund the development of the pump. After the market launch, Gerresheimer will sell the pump to the biotech and receive both a transfer price and royalty. The project is already making a positive contribution to earnings development from the start - clear evidence of the successful implementation of the growth strategy.

The exclusive agreement between Gerresheimer and the American biotech addresses the regions USA and Canada, with a right of first refusal granted to the partner to cover additional territories. Gerresheimer therefore plans to have a pump approved by the United States Food and Drug Administration in the future.

The innovative pump consists of two parts, one of which can be reused, thus increasing the sustainability of the solution. At its core is the already patented SenseCore technology.

Contact Press
Ueli Utzinger
Group Senior Director Communication & Marketing
T +41 79 400 86 40
ueli.utzinger@gerresheimer.com

Contact Investor Relations
Carolin Nadilo
Corporate Senior Director Investor Relations
T +49 211 6181-220
carolin.nadilo@gerresheimer.com

About Gerresheimer
Gerresheimer is the global partner for pharma, biotech, healthcare and cosmetics with a very broad product range for pharma and cosmetics packaging and drug delivery devices. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high degree of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centres in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 10,000 employees and generates annual sales of more than €1.4 billion. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.



End of Media Release


Issuer: Gerresheimer AG
Key word(s): Enterprise

16.12.2021 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Gerresheimer AG
Klaus-Bungert-Str. 4
40468 Düsseldorf
Germany
Phone: +49-(0)211/61 81-314
Fax: +49-(0)211/61 81-121
E-mail: carolin.nadilo@gerresheimer.com
Internet: http://www.gerresheimer.com
ISIN: DE000A0LD6E6
WKN: A0LD6E
Indices: MDAX (Aktie)
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1258818

 
End of News DGAP Media

1258818  16.12.2021 

fncls.ssp?fn=show_t_gif&application_id=1258818&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Gerresheimer AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.